<DOC>
	<DOC>NCT01381107</DOC>
	<brief_summary>This is a multicenter, randomized, double-blind, placebo-controlled, parallel, multiple dose study designed to evaluate the safety and tolerability of the co-formulation of ALKS 33 with buprenorphine (ALKS 5461) in subjects with Major Depressive Disorder (MDD) who are inadequately/partially responding to current treatment with a stable dose of a serotonin-selective reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).</brief_summary>
	<brief_title>ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>ALKS-33</mesh_term>
	<criteria>Male and female subjects between 18 and 65 years of age, inclusive. Meet Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSMIVTR) criteria for MDD. Current episode lasting ≥8 weeks prior to screening with an inadequate/partial response to an adequate trial (defined as at least 8 weeks) of a stable dose of an SSRI or SNRI. Inadequate/partial response is defined as: 1. A Hamilton Depression Rating Scale total score (HAMD17) ≥14, and 2. Less than 50% reduction in depressive symptom severity on the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ), and 3. Clinical Global Impression Severity (CGIS) score of ≥3. Axis I diagnosis of delirium, dementia, amnestic or other cognitive disorder, schizophrenia or other psychotic disorder, bipolar I or II disorder, eating disorder, obsessivecompulsive disorder, panic disorder, or posttraumatic stress disorder. A clinically significant current Axis II diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder. Experiencing hallucinations, delusions, or any psychotic symptomatology in the current episode. The use of inducers or inhibitors of cytochrome P450 (CYP) 3A4 (prescription medications, overthecounter [OTC] medications, or dietary supplements) within 30 days before dosing. Have received electroconvulsive therapy during the current MDD episode. Pose current suicide risk as confirmed by the Columbia Suicide Severity Rating Scale (C SSRS). History of intolerance or hypersensitivity to buprenorphine. History of allergy or hypersensitivity to opioid antagonists (eg, naltrexone, naloxone) or quinine.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>